BioMarin Announces Positive Data From Cerliponase Alfa Program for Treatment of CLN2 Disease, a Form of Batten Disease, at 12th Annual WORLDSymposium(TM) 2016
March 02, 2016 19:05 ET
|
BioMarin Pharmaceutical Inc.
80% Reduction in Clinical Disease Progression in One Year Compared to Natural History (p <0.0001) Company Plans to Submit Marketing Applications Starting Mid-Year 2016 SAN RAFAEL, Calif., March...
BioMarin Announces 21 Presentations at 12th Annual WORLDSymposium™ 2016 February 29-March 4 in San Diego, California: 6 Oral and 15 Poster
February 29, 2016 08:25 ET
|
BioMarin Pharmaceutical Inc.
SAN RAFAEL, Calif., Feb. 29, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that the company will present data in six oral and 15 poster presentations at the...